Paris, France and Cambridge, Massachusetts (USA), 10 June 2020 – CURADIGM today announced the publication, with Prof. Robert Langer’s lab at MIT, of pre-clinical in vivo results showing that its Nanoprimer can improve the efficacy of RNA-based therapeutics. This collaboration utilized next-generation RNA technology developed at the Langer Lab, in combination with Curadigm’s proprietary “Nanoprimer” technology. The Nanoprimer is designed to precisely, but transiently, occupy the hepatic pathways responsible for therapeutic clearance. In pre-clinical studies, the combination resulted in significantly increased bioavailability and efficacy of siRNA and mRNA in vivo.

Published in Nano Letters—one of the premier nanotechnology journals—the results are the culmination of a 2-year research collaboration evaluating the utility of the Curadigm’s Nanoprimer in increasing the efficacy of nucleic-acid based therapeutics. Combined with mRNA and siRNA-based therapeutics, the Nanoprimer increased efficacy by 32% and 49% respectively in the study. This was correlated with decreased liver trapping and increased blood bioavailability of 8 and 16- fold, respectively, without any additional associated toxicity.

Nucleic acid-based therapeutics (RNA and DNA) represent a rapidly growing segment of the biotech and pharma market, showing nearly exponential growth in programs over the last decade. While RNA-based therapeutics hold great potential to treat diverse and challenging diseases, their clinical utility has been limited by the difficulty achieving efficient accumulation in target tissues. This is largely due to the rapid liver clearance of RNA and DNA-based therapeutics. This promising new data, highlights the potential for the Nanoprimer technology to enable greater efficacy for nucleic acid-based therapeutics, facilitate their advancement toward the clinic and strengthen their ability to efficiently target a diverse range of tissues, including non-liver.

This collaboration provides validation of Curadigm’s approach to increasing therapeutic bioavailability and efficacy. The Nanoprimer technology is broadly applicable across multiple drug classes including nanomedicines, nucleic acid therapeutics, and gene editing technologies. The system does not modify the therapeutic at all, rather it is a precisely designed nanoparticle that is administered just prior to a therapeutic and works on a universal liver clearance mechanism for intravenous (IV) therapeutics.

Paris, France and Cambridge, Massachusetts, USA, May 28, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the launch of new subsidiary Curadigm, dedicated to redefining the therapeutic balance between bioavailability, toxicity, and efficacy across the pharmaceutical industry. The company will be a wholly-owned subsidiary of Nanobiotix and operate in France and in the US with a dedicated team committed to growth and potential financing opportunities.

For most therapeutics today, only a small portion of the medicine administered is effective and the rest is cleared from the body without effect or may even be toxic. After injection, the dose moves through the circulatory system within the blood, and while a small portion reaches the targeted tissue the remainder is cleared or accumulates in organs such as the liver. (See illustration)

Curadigm nanotechnology aims to change this balance through proprietary “Nanoprimer” technology. Leveraging over 15 years of experience in the development of nanotechnology at Nanobiotix, the company has created nano-scale objects that prime the body for treatment. These nanoparticles, called nanoprimers, have been designed with specific physico- chemical properties that allow them to transiently occupy the liver cells responsible for therapeutic clearance. Injected prior to the therapeutic, the nanoprimer increases systemic bioavailability allowing for increased accrual in the target tissue and therapeutic action.

Curadigm nanotechnology shows potential to have broad implications across the healthcare system through its opportunity to increase the efficacy of therapeutics at their current dose, lower the necessary dose thereby decreasing toxicity and cost, and allow for novel therapeutic approaches (e.g. new approaches to drug design). In Vivo data proving the concept was published by Nanobiotix in Scientific Reports1 and presented at AACR2019².

Curadigm will be led by Dr. Matthieu Germain, who holds deep expertise in the development of nanoparticles after more than 15 years with Nanobiotix, including initial development of the new technology. Dr. Kate Rochlin, leveraging her strong background in early stage company growth, will join the company as Director of Business Development. Under their leadership, Curadigm will maintain the same core values and spirit of its parent company—to significantly improve outcomes for millions of patients through a disruptive approach for therapeutics across healthcare.